Publicaciones en colaboración con investigadores/as de Imperial College London (20)

2024

  1. Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators

    Journal of Prevention of Alzheimer's Disease

2022

  1. Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease

    Nature Reviews Neurology, Vol. 18, Núm. 4, pp. 203-220

  2. Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis

    Movement Disorders, Vol. 37, Núm. 5, pp. 1028-1039

2021

  1. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

    International Journal of Geriatric Psychiatry, Vol. 36, Núm. 2, pp. 324-333

  2. Dissociable effects of age and Parkinson's disease on instruction-based learning

    Brain Communications, Vol. 3, Núm. 3

  3. Iron and inflammation: in vivo and post-mortem studies in Parkinson’s disease

    Journal of Neural Transmission, Vol. 128, Núm. 1, pp. 15-25

  4. Is chelation therapy a potential treatment for parkinson’s disease?

    International Journal of Molecular Sciences, Vol. 22, Núm. 7

  5. Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients

    Parkinsonism and Related Disorders, Vol. 87, pp. 61-69

2020

  1. Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson's disease

    NeuroImage: Clinical, Vol. 28

2019

  1. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, pp. 301-309

  2. Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system

    Brain, Vol. 142, Núm. 7, pp. 2023-2036

2018

  1. 11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

    Movement Disorders, Vol. 33, Núm. 1, pp. 117-127

  2. Patterns of grey matter loss associated with motor subscores in early Parkinson's disease

    NeuroImage: Clinical, Vol. 17, pp. 498-504

2017

  1. Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review

    Neurological Sciences, Vol. 38, Núm. 12, pp. 2095-2101

  2. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility

    European Journal of Neurology, Vol. 24, Núm. 2, pp. 357-365

  3. Neuromelanin in parkinsonian disorders: an update

    International Journal of Neuroscience, Vol. 127, Núm. 12, pp. 1116-1123

  4. Protocol of a single group prospective observational study on the diagnostic value of 3T susceptibility weighted MRI of nigrosome-1 in patients with parkinsonian symptoms: The N3 i PD study (nigrosomal i ron i maging i n Parkinson's disease)

    BMJ Open, Vol. 7, Núm. 12

2016

  1. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

    Science Translational Medicine, Vol. 8, Núm. 341

2015

  1. Decoding brain state transitions in the pedunculopontine nucleus: Cooperative phasic and tonic mechanisms

    Frontiers in Neural Circuits, Vol. 9, Núm. OCTOBER, pp. 1-16

  2. Other Hypokinetic Parkinsonian Syndromes

    Brain Mapping: An Encyclopedic Reference (Elsevier Inc.), pp. 731-736